<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-09-22" updated="2019-12-02">
  <drugbank-id primary="true">DB09116</drugbank-id>
  <name>Calcium carbimide</name>
  <description>Calcium carbimide, sold as the citrate salt, is an alcohol-sensitizing agent. Its effects are similar to the drug disulfiram (Antabuse) in that it interferes with the normal metabolism of alcohol by preventing the breakdown of the metabolic product acetaldehyde. Calcium carbimide was conceived as an alternative for the treatment of alcoholism with a reduced side effect profile either when it is consumed accompanied by alcohol or without it.[A31516] This drug was developed by Lederle Cyanamid Canada Inc and approved for marketing in Canada in 1959. The current status of calcium carbimide is cancelled post marketing.[L1113]</description>
  <cas-number>156-62-7</cas-number>
  <unii>ZLR270912W</unii>
  <average-mass>80.103</average-mass>
  <monoisotopic-mass>79.9687389</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>withdrawn</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A31516</ref-id>
        <pubmed-id>13316670</pubmed-id>
        <citation>ARMSTRONG JD, KERR HT: A new protective drug in the treatment of alcoholism; preliminary clinical trial of citrated calcium carbimide. Can Med Assoc J. 1956 May 15;74(10):795-7.</citation>
      </article>
      <article>
        <ref-id>A31517</ref-id>
        <pubmed-id>4888318</pubmed-id>
        <citation>Mukasa H, Arikawa K: A new double medication method for the treatment of alcoholism using the drug cyanamide. Kurume Med J. 1968;15(3):137-43.</citation>
      </article>
      <article>
        <ref-id>A31520</ref-id>
        <pubmed-id>3358883</pubmed-id>
        <citation>Jones AW, Neiman J, Hillbom M: Concentration-time profiles of ethanol and acetaldehyde in human volunteers treated with the alcohol-sensitizing drug, calcium carbimide. Br J Clin Pharmacol. 1988 Feb;25(2):213-21.</citation>
      </article>
      <article>
        <ref-id>A31521</ref-id>
        <pubmed-id>3426682</pubmed-id>
        <citation>Jones AW, Neiman J, Hillbom M: Elimination kinetics of ethanol and acetaldehyde in healthy men during the calcium carbimide-alcohol flush reaction. Alcohol Alcohol Suppl. 1987;1:213-7.</citation>
      </article>
      <article>
        <ref-id>A31522</ref-id>
        <pubmed-id>10826131</pubmed-id>
        <citation>Colom H, Prunonosa J, Peraire C, Domenech J, Azcona O, Torrent J, Obach R: Absolute bioavailability and absorption profile of cyanamide in man. J Pharmacokinet Biopharm. 1999 Aug;27(4):421-36.</citation>
      </article>
    </articles>
    <textbooks>
      <textbook>
        <ref-id>T74</ref-id>
        <isbn/>
        <citation>Barh D., Dhawan D. and Ganguly NK. (2013). Omics for personalized medicine. Springer.</citation>
      </textbook>
      <textbook>
        <ref-id>T75</ref-id>
        <isbn/>
        <citation>Vasiliou V. and Petersen D. (2010). Comprehensive toxicology (2nd ed., pp. 131-147). Elsevier.</citation>
      </textbook>
    </textbooks>
    <links>
      <link>
        <ref-id>L1113</ref-id>
        <title>Health Canada</title>
        <url>https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do</url>
      </link>
      <link>
        <ref-id>L1114</ref-id>
        <title>Encyclopedia</title>
        <url>http://www.encyclopedia.com/education/encyclopedias-almanacs-transcripts-and-maps/calcium-carbimide</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Calcium carbimide has not been approved by the FDA but the intended indication is for the treatment of alcoholism.[T74] This medication was marketed in Canada, United Kingdom and Europe under the trade name of Temposil for the sole use of alcoholism treatment.[L1114]</indication>
  <pharmacodynamics>Administration of calcium carbimide causes a syndrome characterized by intense flushing, rapid pulse, panting respiration and perception of acetaldehyde in the exhaled breath. This syndrome remains for a few hours after alcohol consumption and it stops completeley after 24 hours. This syndrome is caused by the accumulation of acetaldehyde and altered vascular reaction.[A31517] Therefore, the more the alcohol consumption the more the adverse effects caused by acetaldehyde accumulation.</pharmacodynamics>
  <mechanism-of-action>Calcium carbimide is a potent inhibitor of the aldehyde dehydrogenase.[T74] Ethanol is normally metabolized to acetaldehyde that is quickly metabolized because this molecule is toxic, thus it has to stay in very low quantities in the body. Carbimide performs its effect by being a competitive inhibitor of the hepatic aldehyde-NAD oxidoreductase dehydrogenase which is the enzyme responsible for the oxidation of acetaldehyde to water and acetate.[L1114]</mechanism-of-action>
  <toxicity>Calcium carbimide presents antithyroid activity which can be of clinical relevance in patients with preexisting hypothyroid disease. It can also present some other minor side effects as fatigue, skin rash, ear ringing, mild depression, increased urination and impotence.[L1114]</toxicity>
  <metabolism>The activity of calcium carbimide requires an initial metabolic transformation to the bioactive form. The transformation requires the activity of catalase and the presence of H2O2 for the formation of N-hydroxycyanamide. This bioactive compound will later spontaneosly decompose into cyanide and nitroxyl. The nitroxyl component will be the direct inhibitor of the aldehyde dehydrogenase.[T75]</metabolism>
  <absorption>It presents a very rapid absorption which has caused the presence of side effects as nausea, headache and vomiting.[L1114] The oral bioavailability of calcium carbimide depends on the administered dose which can vary from 50-81% on a dose of 0.3-1.5 mg/kg respectively.[T74] In preclinical trials, peak plasma concentration occurred at 60 minutes after administration.[L1114] The values of Cmax, AUC and T max of calcium carbimide of a dose of 1.5 mg/kg were 1.65 mcg/ml, 77.86 mcg/mg min and 12 minutes respectively.[A31522]</absorption>
  <half-life>Calcium carbimide is metabolized and eliminated very rapidly so the apparent half-life is of 92.4 minutes.[L1114]</half-life>
  <protein-binding>The metabolism and elimination of calcium carbimide is very rapid, which makes it unlikely to bind to plasma proteins.</protein-binding>
  <route-of-elimination>The rate of elimination of ethanol when calcium carbimide is administered tends to be around 5% slower than the one presented in patients without any treatment. In the presence of calcium carbimide, the blood levels of acetaldehyde were increased from 1.7-6.5 microM to 40-242 microM.[A31521]</route-of-elimination>
  <volume-of-distribution>The apparent volume of distribution of ethanol in the presence of calcium carbimide is 0.64 l/kg compared to 0.68 l/kg when administered in the absence of any drug.[A31520] All the reports studying the pharmacokinetic profile of ethanol after administered with calcium carbimide agree with a reduced volume of distribution driven by the effect of calcium carbimide.</volume-of-distribution>
  <clearance>After intravenous administration of calcium carbimide, there was a two compartment pharmacokinetic profile with a total plasma clearance rate ranging from 0.0123 to 0.0190 L/kg min.[A31522]</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as carbodiimides. These are organic compounds containing a functional group consisting of the formula RN=C=NR.</description>
    <direct-parent>Carbodiimides</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic nitrogen compounds</superclass>
    <class>Organonitrogen compounds</class>
    <subclass>Carbodiimides</subclass>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic calcium salts</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <substituent>Aliphatic acyclic compound</substituent>
    <substituent>Carbodiimide</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic calcium salt</substituent>
    <substituent>Organic salt</substituent>
    <substituent>Organopnictogen compound</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001860</drugbank-id>
      <name>Citrated calcium carbimide</name>
      <unii>21ZCD2AA4H</unii>
      <cas-number>8013-88-5</cas-number>
      <inchikey>NEZBLMYXHFALIF-UHFFFAOYSA-N</inchikey>
      <average-mass>292.301</average-mass>
      <monoisotopic-mass>292.0583418</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="inn">Calcium carbimide</synonym>
    <synonym language="english" coder="">calcium cyanamide</synonym>
    <synonym language="spanish" coder="inn">carbimida calcica</synonym>
    <synonym language="french" coder="inn">carbimide calcique</synonym>
    <synonym language="french" coder="">Cyanamide calcique</synonym>
    <synonym language="english" coder="">Cyanamide, calcium salt (1:1)</synonym>
    <synonym language="english" coder="">Lime nitrogen</synonym>
    <synonym language="english" coder="">Lime-nitrogen</synonym>
    <synonym language="english" coder="">methanediimine, calcium salt (1:1)</synonym>
    <synonym language="english" coder="">Nitrogen lime</synonym>
  </synonyms>
  <products>
    <product>
      <name>Temposil Tab 50mg</name>
      <labeller>Lederle Cyanamid Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00014958</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1959-12-31</started-marketing-on>
      <ended-marketing-on>1999-04-12</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Temposil Tab 50mg</name>
      <ingredients>Calcium carbimide</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Drugs Used in Addictive Disorders</category>
      <mesh-id/>
    </category>
    <category>
      <category>Drugs Used in Alcohol Dependence</category>
      <mesh-id/>
    </category>
    <category>
      <category>Nervous System</category>
      <mesh-id>D009420</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="N07BB02">
      <level code="N07BB">Drugs used in alcohol dependence</level>
      <level code="N07B">DRUGS USED IN ADDICTIVE DISORDERS</level>
      <level code="N07">OTHER NERVOUS SYSTEM DRUGS</level>
      <level code="N">NERVOUS SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Ethanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00822</drugbank-id>
      <name>Disulfiram</name>
      <description>The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Disulfiram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01534</drugbank-id>
      <name>Chlorhexadol</name>
      <description>The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Chlorhexadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02178</drugbank-id>
      <name>Phenylacetaldehyde</name>
      <description>The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Phenylacetaldehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03057</drugbank-id>
      <name>Malonaldehyde</name>
      <description>The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Malonaldehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03174</drugbank-id>
      <name>Phosphonoacetaldehyde</name>
      <description>The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Phosphonoacetaldehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03266</drugbank-id>
      <name>Glutaral</name>
      <description>The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Glutaral.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03560</drugbank-id>
      <name>P-Hydroxybenzaldehyde</name>
      <description>The risk or severity of adverse effects can be increased when Calcium carbimide is combined with P-Hydroxybenzaldehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03587</drugbank-id>
      <name>Pyruvaldehyde</name>
      <description>The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Pyruvaldehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13027</drugbank-id>
      <name>Tucaresol</name>
      <description>The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Tucaresol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14184</drugbank-id>
      <name>Cinnamaldehyde</name>
      <description>The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Cinnamaldehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03843</drugbank-id>
      <name>Formaldehyde</name>
      <description>The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Formaldehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11268</drugbank-id>
      <name>Protocatechualdehyde</name>
      <description>The risk or severity of adverse effects can be increased when Calcium carbimide is combined with Protocatechualdehyde.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>0.04</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-1.2</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>8.71e+00 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-0.25</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>calcium (azanidylenemethylidene)azanide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>calcium (azanidylenemethylidene)azanide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>80.103</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>79.9687389</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[Ca++].[N-]=C=[N-]</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>CCaN2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/CN2.Ca/c2-1-3;/q-2;+2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>MYFXBBAEXORJNB-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>34.14</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>6.38</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>2.91</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>3.56</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Soluble </value>
      <source>Perry D. Handbook of Inorganic compounds. Second edition. (2011)</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>1300ºC</value>
      <source>Perry D. Handbook of Inorganic compounds. Second edition. (2011)</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>Sublimes 1150-1200ºC</value>
      <source>Perry D. Handbook of Inorganic compounds. Second edition. (2011)</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>5868</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>64301</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>56955933</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>310265033</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C19113</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D03288</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>21106503</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Calcium_cyanamide</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL3301667</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB09116</drugbank-id>
        <name>Calcium carbimide</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01896</drugbank-id>
        <name>N-hydroxycynamide</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0001207</drugbank-id>
          <name>Catalase</name>
          <uniprot-id>P04040</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DBMET01896</drugbank-id>
        <name>N-hydroxycynamide</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01897</drugbank-id>
        <name>cyanide</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DBMET01896</drugbank-id>
        <name>N-hydroxycynamide</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01898</drugbank-id>
        <name>nitroxyl</name>
      </right-element>
      <enzymes/>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000193</id>
      <name>Aldehyde dehydrogenase family 3 member B2</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L1114</ref-id>
            <title>Encyclopedia</title>
            <url>http://www.encyclopedia.com/education/encyclopedias-almanacs-transcripts-and-maps/calcium-carbimide</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P48448" source="Swiss-Prot">
        <name>Aldehyde dehydrogenase family 3 member B2</name>
        <general-function>Aldehyde dehydrogenase [nad(p)+] activity</general-function>
        <specific-function/>
        <gene-name>ALDH3B2</gene-name>
        <locus>11q13</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.97</theoretical-pi>
        <molecular-weight>42634.6</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:411</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ALDH3B2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U37519</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1051281</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P48448</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>AL3B2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.2.1.5</synonym>
          <synonym>Aldehyde dehydrogenase 8</synonym>
          <synonym>ALDH8</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009995|Aldehyde dehydrogenase family 3 member B2
MKDEPRSTNLFMKLDSVFIWKEPFGLVLIIAPWNYPLNLTLVLLVGALAAGSCVVLKPSE
ISQGTEKVLAEVLPQYLDQSCFAVVLGGPQETGQLLEHKLDYIFFTGSPRVGKIVMTAAT
KHLTPVTLELGGKNPCYVDDNCDPQTVANRVAWFCYFNAGQTCVAPDYVLCSPEMQERLL
PALQSTITRFYGDDPQSSPNLGHIINQKQFQRLRALLGCSRVAIGGQSNESDRYIAPTVL
VDVQETEPVMQEEIFGPILPIVNVQSVDEAIKFINRQEKPLALYAFSNSSQVVNQMLERT
SSGSFGGNEGFTYISLLSVPFGGVGHSGMGRYHGKFTFDTFSHHRTCLLAPSGLEKLKEI
HYPPYTDWNQQLLRWGMGSQSCTLL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0009996|Aldehyde dehydrogenase family 3 member B2 (ALDH3B2)
ATGAAGGATGAACCACGGTCCACGAACCTGTTCATGAAGCTGGACTCGGTCTTCATCTGG
AAGGAACCCTTTGGCCTGGTCCTCATCATCGCACCCTGGAACTACCCACTGAACCTGACC
CTGGTGCTCCTGGTGGGCGCCCTCGCCGCAGGGAGTTGCGTGGTGCTGAAGCCGTCAGAA
ATCAGCCAGGGCACAGAGAAGGTCCTGGCTGAGGTGCTGCCCCAGTACCTGGACCAGAGC
TGCTTTGCCGTGGTGCTGGGCGGACCCCAGGAGACAGGGCAGCTGCTAGAGCACAAGTTG
GACTACATCTTCTTCACAGGGAGCCCTCGTGTGGGCAAGATTGTCATGACTGCTGCCACC
AAGCACCTGACGCCTGTCACCCTGGAGCTGGGGGGCAAGAACCCCTGCTACGTGGACGAC
AACTGCGACCCCCAGACCGTGGCCAACCGCGTGGCCTGGTTCTGCTACTTCAATGCCGGC
CAGACCTGCGTGGCCCCTGACTACGTCCTGTGCAGCCCCGAGATGCAGGAGAGGCTGCTG
CCCGCCCTGCAGAGCACCATCACCCGTTTCTATGGCGACGACCCCCAGAGCTCCCCAAAC
CTGGGCCGCATCATCAACCAGAAACAGTTCCAGCGGCTGCGGGCATTGCTGGGCTGCGGC
CGCGTGGCCATTGGGGGCCAGAGCAACGAGAGCGATCGCTACATCGCCCCCACGGTGCTG
GTGGACGTGCAGGAGACGGAGCCTGTGATGCAGGAGGAGATCTTCGGGCCCATCCTGCCC
ATCGTGAACGTGCAGAGCGTGGACGAGGCCATCAAGTTCATCAACCGGCAGGAGAAGCCC
CTGGCCCTGTACGCCTTCTCCAACAGCAGCCAGGTTGTGAACCAGATGCTGGAGCGGACC
AGCAGCGGCAGCTTTGGAGGCAATGAGGGCTTCACCTACATATCTCTGCTGTCCGTGCCA
TTCGGGGGAGTCGGCCACAGTGGGATGGGCCGGTACCACGGCAAGTTCACCTTCGACACC
TTCTCCCACCACCGCACCTGCCTGCTCGCCCCCTCCGGCCTGGAGAAATTAAAGGAGATC
CACTACCCACCCTATACCGACTGGAACCAGCAGCTGTTACGCTGGGGCATGGGCTCCCAG
AGCTGCACCCTCCTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00171</identifier>
            <name>Aldedh</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>function</category>
            <description>3-chloroallyl aldehyde dehydrogenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aldehyde dehydrogenase (NAD) activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aldehyde dehydrogenase [NAD(P)+] activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alcohol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ethanol catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="2">
      <id>BE0001207</id>
      <name>Catalase</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles/>
        <textbooks>
          <textbook>
            <ref-id>T75</ref-id>
            <isbn/>
            <citation>Vasiliou V. and Petersen D. (2010). Comprehensive toxicology (2nd ed.). Elsevier.</citation>
          </textbook>
        </textbooks>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P04040" source="Swiss-Prot">
        <name>Catalase</name>
        <general-function>Receptor binding</general-function>
        <specific-function>Occurs in almost all aerobically respiring organisms and serves to protect cells from the toxic effects of hydrogen peroxide. Promotes growth of cells including T-cells, B-cells, myeloid leukemia cells, melanoma cells, mastocytoma cells and normal and transformed fibroblast cells.</specific-function>
        <gene-name>CAT</gene-name>
        <locus>11p13</locus>
        <cellular-location>Peroxisome</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.41</theoretical-pi>
        <molecular-weight>59755.82</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1516</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CAT</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X04085</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1228085</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P04040</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CATA_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.11.1.6</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0020512|Catalase
MADSRDPASDQMQHWKEQRAAQKADVLTTGAGNPVGDKLNVITVGPRGPLLVQDVVFTDE
MAHFDRERIPERVVHAKGAGAFGYFEVTHDITKYSKAKVFEHIGKKTPIAVRFSTVAGES
GSADTVRDPRGFAVKFYTEDGNWDLVGNNTPIFFIRDPILFPSFIHSQKRNPQTHLKDPD
MVWDFWSLRPESLHQVSFLFSDRGIPDGHRHMNGYGSHTFKLVNANGEAVYCKFHYKTDQ
GIKNLSVEDAARLSQEDPDYGIRDLFNAIATGKYPSWTFYIQVMTFNQAETFPFNPFDLT
KVWPHKDYPLIPVGKLVLNRNPVNYFAEVEQIAFDPSNMPPGIEASPDKMLQGRLFAYPD
THRHRLGPNYLHIPVNCPYRARVANYQRDGPMCMQDNQGGAPNYYPNSFGAPEQQPSALE
HSIQYSGEVRRFNTANDDNVTQVRAFYVNVLNEEQRKRLCENIAGHLKDAQIFIQKKAVK
NFTEVHPDYGSHIQALLDKYNAEKPKNAIHTFVQSGSHLAAREKANL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020513|Catalase (CAT)
ATGGCTGACAGCCGGGATCCCGCCAGCGACCAGATGCAGCACTGGAAGGAGCAGCGGGCC
GCGCAGAAAGCTGATGTCCTGACCACTGGAGCTGGTAACCCAGTAGGAGACAAACTTAAT
GTTATTACAGTAGGGCCCCGTGGGCCCCTTCTTGTTCAGGATGTGGTTTTCACTGATGAA
ATGGCTCATTTTGACCGAGAGAGAATTCCTGAGAGAGTTGTGCATGCTAAAGGAGCAGGG
GCCTTTGGCTACTTTGAGGTCACACATGACATTACCAAATACTCCAAGGCAAAGGTATTT
GAGCATATTGGAAAGAAGACTCCCATCGCAGTTCGGTTCTCCACTGTTGCTGGAGAATCG
GGTTCAGCTGACACAGTTCGGGACCCTCGTGGGTTTGCAGTGAAATTTTACACAGAAGAT
GGTAACTGGGATCTCGTTGGAAATAACACCCCCATTTTCTTCATCAGGGATCCCATATTG
TTTCCATCTTTTATCCACAGCCAAAAGAGAAATCCTCAGACACATCTGAAGGATCCGGAC
ATGGTCTGGGACTTCTGGAGCCTACGTCCTGAGTCTCTGCATCAGGTTTCTTTCTTGTTC
AGTGATCGGGGGATTCCAGATGGACATCGCCACATGAATGGATATGGATCACATACTTTC
AAGCTGGTTAATGCAAATGGGGAGGCAGTTTATTGCAAATTCCATTATAAGACTGACCAG
GGCATCAAAAACCTTTCTGTTGAAGATGCGGCGAGACTTTCCCAGGAAGATCCTGACTAT
GGCATCCGGGATCTTTTTAACGCCATTGCCACAGGAAAGTACCCCTCCTGGACTTTTTAC
ATCCAGGTCATGACATTTAATCAGGCAGAAACTTTTCCATTTAATCCATTCGATCTCACC
AAGGTTTGGCCTCACAAGGACTACCCTCTCATCCCAGTTGGTAAACTGGTCTTAAACCGG
AATCCAGTTAATTACTTTGCTGAGGTTGAACAGATAGCCTTCGACCCAAGCAACATGCCA
CCTGGCATTGAGGCCAGTCCTGACAAAATGCTTCAGGGCCGCCTTTTTGCCTATCCTGAC
ACTCACCGCCATCGCCTGGGACCCAATTATCTTCATATACCTGTGAACTGTCCCTACCGT
GCTCGAGTGGCCAACTACCAGCGTGACGGCCCGATGTGCATGCAGGACAATCAGGGTGGT
GCTCCAAATTACTACCCCAACAGCTTTGGTGCTCCGGAACAACAGCCTTCTGCCCTGGAG
CACAGCATCCAATATTCTGGAGAAGTGCGGAGATTCAACACTGCCAATGATGATAACGTT
ACTCAGGTGCGGGCATTCTATGTGAACGTGCTGAATGAGGAACAGAGGAAACGTCTGTGT
GAGAACATTGCCGGCCACCTGAAGGATGCACAAATTTTCATCCAGAAGAAAGCGGTCAAG
AACTTCACTGAGGTCCACCCTGACTACGGGAGCCACATCCAGGCTCTTCTGGACAAGTAC
AATGCTGAGAAGCCTAAGAATGCGATTCACACCTTTGTGCAGTCCGGATCTCACTTGGCG
GCAAGGGAGAAGGCAAATCTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00199</identifier>
            <name>Catalase</name>
          </pfam>
          <pfam>
            <identifier>PF06628</identifier>
            <name>Catalase-rel</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>focal adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial intermembrane space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>peroxisomal matrix</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>peroxisomal membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>peroxisome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aminoacylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>antioxidant activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>catalase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>NADP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on peroxide as acceptor</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aerobic respiration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to growth factor stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cholesterol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hemoglobin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hydrogen peroxide catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of NF-kappaB transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleobase-containing small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>osteoblast differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell division</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NF-kappaB transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of phosphatidylinositol 3-kinase signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein homotetramerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein tetramerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>purine nucleobase metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>purine nucleotide catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cadmium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to fatty acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hydrogen peroxide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hyperoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to inactivity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to insulin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to L-ascorbic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lead ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to light intensity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ozone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to phenylpropanoid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to reactive oxygen species</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to toxic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin A</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin E</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>triglyceride metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ureteric bud development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>UV protection</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>